Voting Questions for the Committee

1. For the composition of egg-based trivalent 2022 SH formulations of influenza vaccines, does the committee recommend:
   A. Inclusion of an A/Victoria/2570/2019 (H1N1)pdm09-like virus
   B. Inclusion of an A/Darwin/9/2021 (H3N2)-like virus
   C. Inclusion of a B/Austria/1359417/2021-like virus (B/Victoria lineage)

2. For quadrivalent 2022 SH formulations of influenza vaccines, does the committee recommend:
   A. Inclusion of a B/Phuket/3073/2013-like virus (B/Yamagata lineage) as the 2nd influenza B strain in the vaccine